Mariya D.
- Country
- Bulgaria
- Department
- Clinic of clinical hematology
Research Overview
- Efficacy and Safety of Acalabrutinib with Venetoclax and Obinutuzumab Versus Chemoimmunotherapy in Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
- Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
Data & Insights
Has run more than one trial at 4 of 71 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL), with particular focus on developing treatment strategies for previously untreated patients without specific genetic mutations.
- Novel Therapeutic Combinations
- First-line Treatment Approaches
- Targeted Therapy Development
Research activities center on evaluating innovative treatment combinations involving targeted therapies and established therapeutic agents.
Precision Medicine
The investigator focuses on personalized treatment approaches in hematologic malignancies, particularly examining therapeutic options based on genetic profiles.
- Genetic Mutation Analysis
- Biomarker-directed Therapy
- Treatment Optimization
Clinical interests include developing treatment strategies for patients with specific molecular characteristics.
Therapeutic Innovation
The investigator evaluates novel drug combinations including targeted agents and immunotherapies for blood cancers.
- Combination Therapy Assessment
- Immunotherapy Applications
- Treatment Safety Evaluation
Research encompasses comparing innovative therapeutic approaches with established treatment standards in hematologic oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.